Skip to main content

Advertisement

SpringerLink
Log in

Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Iron deficiency anemia affects approximately 45% of patients with inflammatory bowel disease (IBD), negatively impacts the quality of life in this patient population, and significantly burdens our healthcare system. The pathogenesis of iron deficiency in IBD patients is multifactorial, including intestinal bleeding, malabsorption, and inadequate oral intake. Regular screening and diagnosis in these patients are imperative, and often patients have mixed iron deficiency anemia and anemia of chronic disease, especially in those with active inflammation. Iron may be replenished either orally or intravenously. While oral iron is safe, affordable, and easy to administer, patients often suffer from intolerable gastrointestinal side effects, and particularly in IBD patients, oral iron may increase inflammation and contribute to flares. Therefore, although it is substantially underused, intravenous (IV) iron is considered first-line treatment for patients with active disease, severe anemia, oral iron intolerance, and erythropoietin requirements. Several IV iron formulations are available, and iron sucrose and ferric carboxymaltose are the most frequently used and well studied in patients with IBD. However, iron isomaltoside could potentially become a popular choice among providers given its safety, efficacy, and convenience. Overall, screening, diagnosis, and treatment of iron deficiency anemia are important in patients with IBD. Individual patient characteristics, risks, and benefits, and advantages and disadvantages, should be considered when determining the best route and formulation for iron repletion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585–595.

    Article  CAS  Google Scholar 

  2. Patel D, Trivedi C, Khan N. Management of anemia in patients with inflammatory bowel disease (IBD). Curr Treat Options Gastroenterol. 2018;16:112–128.

    Article  Google Scholar 

  3. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–1307.

    Article  Google Scholar 

  4. Hou JK, Gasche C, Drazin NZ et al. Assessment of gaps in care and the development of a care pathway for anemia in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23:35–43.

    Article  Google Scholar 

  5. Blaney H, Vu P, Mathew A et al. Anemia severity associated with increased healthcare utilization and costs in inflammatory bowel disease. Dig Dis Sci. 2021;66:2555–2563.

    Article  Google Scholar 

  6. Akpınar H, Çetiner M, Keshav S, Örmeci N, Törüner M. Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report. Turk J Gastroenterol. 2017;28:81–87.

    Article  Google Scholar 

  7. Danese S, Hoffman C, Vel S et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn’s and Ulcerative Colitis Association’s online survey. Eur J Gastroenterol Hepatol. 2014;26:1385–1391.

    Article  CAS  Google Scholar 

  8. Al-Naseem A, Sallam A, Choudhury S, Thachil J. Iron deficiency without anaemia: a diagnosis that matters. Clin Med (Lond). 2021;21:107–113.

    Article  Google Scholar 

  9. Rieder F, Paul G, Schnoy E et al. Hemoglobin and hematocrit levels in the prediction of complicated Crohn’s disease behavior–a cohort study. PLoS ONE. 2014;9:e104706.

    Article  Google Scholar 

  10. Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166:411–423.

    Article  Google Scholar 

  11. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397:233–248.

    Article  CAS  Google Scholar 

  12. Braunstein E. Iron deficiency anemia. In: Merck manual professional version. Merck Publishing; 2021.

  13. González Alayón C, Pedrajas Crespo C, Marín Pedrosa S et al. Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life. Gastroenterol Hepatol. 2018;41:22–29.

    Article  Google Scholar 

  14. DeLoughery TG. Iron deficiency anemia. Med Clin North Am. 2017;101:319–332.

    Article  Google Scholar 

  15. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.

    Article  Google Scholar 

  16. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95(2):199–205.

  17. Shin DH, Kim HS, Park MJ, Suh IB, Shin KS. Utility of access soluble transferrin receptor (sTfR) and sTfR/log Ferritin Index in diagnosing iron deficiency anemia. Ann Clin Lab Sci. 2015;45:396–402.

    CAS  Google Scholar 

  18. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia A meta-analysis. Am J Clin Pathol. 2012;138:642–649.

    Article  Google Scholar 

  19. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.

    Article  Google Scholar 

  20. Shah Y, Patel D, Khan N. Iron deficiency anemia in IBD: an overlooked comorbidity. Expert Rev Gastroenterol Hepatol. 2021;15:771–781.

    Article  CAS  Google Scholar 

  21. Khan N, Patel D, Trivedi C et al. Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk. Am J Gastroenterol. 2021;116:741–747.

    Article  Google Scholar 

  22. Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol. 2014;20:3542–3551.

    Article  Google Scholar 

  23. Subramaniam K, D’Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28:24–30.

    Article  CAS  Google Scholar 

  24. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0117383.

    Article  Google Scholar 

  25. Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine (Baltimore). 2015;94:e963.

    Article  CAS  Google Scholar 

  26. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182–1192.

    Article  CAS  Google Scholar 

  27. Tulewicz-Marti E, Moniuszko A, Rydzewska G. Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice. Prz Gastroenterol. 2017;12:239–243.

    CAS  Google Scholar 

  28. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol. 2007;13:4798–4806.

    Article  CAS  Google Scholar 

  29. Werner T, Wagner SJ, Martínez I et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn’s disease-like ileitis. Gut. 2011;60:325–333.

    Article  CAS  Google Scholar 

  30. Zimmermann MB, Chassard C, Rohner F et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire. Am J Clin Nutr. 2010;92:1406–1415.

    Article  CAS  Google Scholar 

  31. Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: from basic science to clinical practice. Pharmaceuticals (Basel). 2018;11(3).

  32. Nielsen OH, Soendergaard C, Vikner ME, Weiss G. Rational management of iron-deficiency anaemia in inflammatory bowel disease. Nutrients. 2018;10(1).

  33. Gasche C, Ahmad T, Tulassay Z et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579–588.

    Article  Google Scholar 

  34. Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. ScientificWorldJournal. 2012;2012:846824.

    Article  Google Scholar 

  35. Moretti D, Goede JS, Zeder C et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981–1989.

    Article  CAS  Google Scholar 

  36. Stoffel NU, Cercamondi CI, Brittenham G et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4:e524–e533.

    Article  Google Scholar 

  37. Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020;105:1232–1239.

    Article  CAS  Google Scholar 

  38. Li N, Zhao G, Wu W et al. The efficacy and safety of vitamin c for iron supplementation in adult patients with iron deficiency anemia: a randomized clinical trial. JAMA Netw Open. 2020;3:e2023644.

    Article  Google Scholar 

  39. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29:291–303.

    Article  CAS  Google Scholar 

  40. D'Amico F, Peyrin-Biroulet L, Danese S. Oral iron for IBD patients: lessons learned at time of COVID-19 pandemic. J Clin Med. 2020;9(5).

  41. Schmidt C, Ahmad T, Tulassay Z et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther. 2016;44:259–270.

    Article  CAS  Google Scholar 

  42. Kumar A, Brookes MJ. Iron therapy in inflammatory bowel disease. Nutrients. 2020;12(11).

  43. Abbati G, Incerti F, Boarini C et al. Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Intern Emerg Med. 2019;14:423–431.

    Article  Google Scholar 

  44. Auerbach M. Treatment of iron deficiency anemia in adults. In: Robert Means WM, Jennifer Tirnauer, Lisa Kunins, ed. UpToDate.2022.

  45. Bonovas S, Fiorino G, Allocca M et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2308.

    Article  CAS  Google Scholar 

  46. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012;6:267–275.

    Article  Google Scholar 

  47. Avni T, Bieber A, Steinmetz T, Leibovici L, Gafter-Gvili A. Treatment of anemia in inflammatory bowel disease–systematic review and meta-analysis. PLoS ONE. 2013;8:e75540.

    Article  Google Scholar 

  48. Kletzmayr J, Sunder-Plassmann G, Hörl WH. High dose intravenous iron: a note of caution. Nephrol Dial Transplant. 2002;17:962–965.

    Article  CAS  Google Scholar 

  49. Ishida JH, Marafino BJ, McCulloch CE et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for Infection. Clin J Am Soc Nephrol. 2015;10:1799–1805.

    Article  CAS  Google Scholar 

  50. Sullivan JL. Iron therapy and cardiovascular disease. Kidney Int Suppl. 1999;69:S135-137.

    Article  CAS  Google Scholar 

  51. Del Vecchio L, Ekart R, Ferro CJ et al. Intravenous iron therapy and the cardiovascular system: risks and benefits. Clin Kidney J. 2021;14:1067–1076.

    Article  Google Scholar 

  52. Macdougall IC, White C, Anker SD et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380:447–458.

    Article  CAS  Google Scholar 

  53. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100:301–303.

    CAS  Google Scholar 

  54. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–853.e841–842.

  55. Favrat B, Balck K, Breymann C et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women–PREFER a randomized, placebo-controlled study. PLoS ONE. 2014;9:e94217.

    Article  Google Scholar 

  56. Niepel D, Klag T, Malek NP, Wehkamp J. Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818769074.

    Article  Google Scholar 

  57. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004;19:1571–1575.

    Article  CAS  Google Scholar 

  58. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378–382.

    Article  CAS  Google Scholar 

  59. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease—a practical approach. Ann Gastroenterol. 2013;26:104–113.

    Google Scholar 

  60. Lindgren S, Wikman O, Befrits R et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44:838–845.

    Article  CAS  Google Scholar 

  61. Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol. 2009;15:4617–4626.

    Article  Google Scholar 

  62. Schröder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503–2509.

    Article  Google Scholar 

  63. Evstatiev R, Alexeeva O, Bokemeyer B et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269–277.

    Article  CAS  Google Scholar 

  64. Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;6:62–72.

    Article  Google Scholar 

  65. Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28:3301–3314.

    Article  CAS  Google Scholar 

  66. Schaefer B, Zoller H, Wolf M. Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. J Clin Endocrinol Metab. 2021.

  67. Tozzi D, Tozzi J. Osteomalacia and insufficiency fractures secondary to intravenous iron therapy: a case report. J Orthop Case Rep. 2020;10:4–7.

    Google Scholar 

  68. Callejas-Moraga EL, Casado E, Gomez-Nuñez M, Caresia-Aroztegui AP. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Rep. 2020;13:100712.

    Article  Google Scholar 

  69. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018;2018.

  70. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76:74–78.

    Article  CAS  Google Scholar 

  71. Ford DC, Dahl NV, Strauss WE et al. Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders. Clin Exp Gastroenterol. 2016;9:151–162.

    Article  CAS  Google Scholar 

  72. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012;69(4):310–320.

  73. Bruining DH, Loftus EV. Technology insight: new techniques for imaging the gut in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:154–161.

    Article  Google Scholar 

  74. McCullough BJ, Kolokythas O, Maki JH, Green DE. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging. 2013;37:1476–1479.

    Article  Google Scholar 

  75. Auerbach M, Henry D, DeLoughery TG. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. Am J Hematol. 2021;96:727–734.

    Article  CAS  Google Scholar 

  76. Dahlerup JF, Jacobsen BA, van der Woude J, Bark L, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332–1338.

    Article  CAS  Google Scholar 

  77. Stein J, Walper A, Klemm W, Farrag K, Aksan A, Dignass A. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol. 2018;53:1059–1065.

    Article  CAS  Google Scholar 

  78. Sam K, Khan AI, Khan A, et al. Efficacy and safety of ferric derisomaltose/iron isomaltoside in patients with inflammatory bowel disease: a systematic review. In. Vol 138: Blood; 2021.

  79. Detlie TE, Lindstrøm JC, Jahnsen ME et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50:397–406.

    Article  CAS  Google Scholar 

  80. Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303–1318.

    Article  CAS  Google Scholar 

  81. Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: a framework for changing the management of iron deficiency. Lancet Haematol. 2020;7:e342–e350.

    Article  Google Scholar 

  82. Hambley BC, Anderson KE, Shanbhag SP, Sen AP, Anderson G. Payment incentives and the use of higher-cost drugs: a retrospective cohort analysis of intravenous iron in the Medicare population. Am J Manag Care. 2020;26:516–522.

    Article  Google Scholar 

  83. Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol. 2009;15:4675–4685.

    Article  Google Scholar 

  84. Gasche C, Waldhoer T, Feichtenschlager T et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382–2387.

    Article  CAS  Google Scholar 

  85. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med. 1992;120:746–751.

    CAS  Google Scholar 

  86. Carson JL, Stanworth SJ, Alexander JH et al. Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease. Am Heart J. 2018;200:96–101.

    Article  Google Scholar 

  87. García-Erce JA, Gomollón F, Muñoz M. Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases. World J Gastroenterol. 2009;15:4686–4694.

    Article  Google Scholar 

  88. Mei Z, Cogswell ME, Looker AC et al. Assessment of iron status in US pregnant women from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Am J Clin Nutr. 2011;93:1312–1320.

    Article  CAS  Google Scholar 

  89. Auerbach M. Commentary: iron deficiency of pregnancy—a new approach involving intravenous iron. Reprod Health. 2018;15:96.

    Article  Google Scholar 

  90. Mahadevan U, Robinson C, Bernasko N et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Inflamm Bowel Dis. 2019;25:627–641.

    Article  Google Scholar 

  91. Achebe MM, Gafter-Gvili A. How I treat anemia in pregnancy: iron, cobalamin, and folate. Blood. 2017;129:940–949.

    Article  CAS  Google Scholar 

  92. Kitsati N, Liakos D, Ermeidi E et al. Rapid elevation of transferrin saturation and serum hepcidin concentration in hemodialysis patients after intravenous iron infusion. Haematologica. 2015;100:e80-83.

    Article  Google Scholar 

  93. Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104:1460–1467.

    Article  CAS  Google Scholar 

  94. Jimenez KM, Gasche C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Hematol. 2019;142:30–36.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Laura A. Maas and Mahesh Krishna are co-first authors.

Authors and Affiliations

  1. Johns Hopkins Hospital, Baltimore, MD, USA

    Laura A. Maas, Mahesh Krishna & Alyssa M. Parian

Authors
  1. Laura A. Maas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahesh Krishna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alyssa M. Parian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alyssa M. Parian.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maas, L.A., Krishna, M. & Parian, A.M. Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients. Dig Dis Sci 68, 357–369 (2023). https://doi.org/10.1007/s10620-022-07599-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-022-07599-1

Keywords

Search

Navigation